{"id":64299,"date":"2026-04-30T14:15:28","date_gmt":"2026-04-30T06:15:28","guid":{"rendered":"https:\/\/flcube.com\/?p=64299"},"modified":"2026-04-30T14:15:28","modified_gmt":"2026-04-30T06:15:28","slug":"allist-pharmaceuticals-secures-china-btd-for-kras-g12c-nsclc-combination-therapy-with-71-response-rate","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64299","title":{"rendered":"Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate"},"content":{"rendered":"\n<p><strong>Allist Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688578:SHA\">SHA: 688578<\/a>) announced that China&#8217;s regulatory authorities have granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> for its investigational combination of <strong>glecirasib<\/strong> and <strong>AST24082<\/strong> as <strong>first-line treatment<\/strong> for patients with <strong>locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)<\/strong> harboring <strong>KRAS G12C mutations<\/strong> and <strong>PD-L1 expression &lt; 50%<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>China National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Product Combination<\/strong><\/td><td>Glecirasib + AST24082 (oral capsules)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line treatment of KRAS G12C-mutant NSCLC with PD-L1 &lt; 50%<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Locally advanced or metastatic non-squamous NSCLC<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Early clinical exploratory studies completed; pivotal trials expected to follow<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Glecirasib<\/strong>: KRAS G12C inhibitor targeting the specific oncogenic mutation driving tumor growth<\/li>\n\n\n\n<li><strong>AST24082<\/strong>: <strong>Novel, highly selective SHP2 inhibitor<\/strong> in oral capsule form that enhances KRAS pathway inhibition<\/li>\n\n\n\n<li><strong>Combination Rationale<\/strong>: Dual blockade of KRAS G12C and SHP2 produces <strong>synergistic anti-tumor effects<\/strong> by comprehensively inhibiting the MAPK signaling pathway<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Oral regimen offering potential convenience advantages over intravenous standard-of-care therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-data-early-exploratory-studies\">Clinical Data \u2013 Early Exploratory Studies<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Patient Population<\/strong><\/td><td>First-line advanced KRAS G12C-mutant NSCLC<\/td><\/tr><tr><td><strong>Median Follow-up<\/strong><\/td><td>14.4 months<\/td><\/tr><tr><td><strong>Confirmed Objective Response Rate (ORR)<\/strong><\/td><td>71%<\/td><\/tr><tr><td><strong>Median Progression-Free Survival (PFS)<\/strong><\/td><td>12.2 months<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Manageable with no unexpected toxicities<\/td><\/tr><tr><td><strong>Comparative Benchmark<\/strong><\/td><td>Superior efficacy vs. current first-line standard (immunotherapy + chemotherapy)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Population Size<\/strong><\/td><td>KRAS G12C mutations occur in ~13% of NSCLC cases in China, representing ~80,000 annual incident cases<\/td><\/tr><tr><td><strong>Current Standard of Care<\/strong><\/td><td>PD-1\/PD-L1 immunotherapy combined with platinum-based chemotherapy for PD-L1 &lt; 50% patients<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>Limited targeted therapy options for KRAS G12C-mutant NSCLC in first-line setting<\/td><\/tr><tr><td><strong>Competitive Differentiation<\/strong><\/td><td>First oral combination specifically targeting KRAS G12C + SHP2 pathway in Chinese development<\/td><\/tr><tr><td><strong>Global Context<\/strong><\/td><td>Builds on emerging global interest in KRAS G12C inhibitors (e.g., sotorasib, adagrasib) with novel combination approach<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-commercial-outlook\">Strategic Implications &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage<\/strong>: Potential to become first approved targeted therapy for KRAS G12C-mutant NSCLC in China&#8217;s first-line setting<\/li>\n\n\n\n<li><strong>Market Premium<\/strong>: Targeted therapies typically command significant pricing premiums over chemotherapy-based regimens<\/li>\n\n\n\n<li><strong>Development Acceleration<\/strong>: BTD status enables expedited regulatory review and potential priority approval pathways<\/li>\n\n\n\n<li><strong>Global Expansion Potential<\/strong>: Strong clinical data could support international partnerships or regulatory filings in other markets<\/li>\n\n\n\n<li><strong>Pipeline Validation<\/strong>: Success validates Allist&#8217;s precision oncology strategy and SHP2 inhibitor platform technology<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory outcomes, and commercial potential. Actual results may differ due to risks including pivotal trial outcomes, regulatory decisions, and competitive developments in the KRAS-targeted therapy space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688578_20260430_WREW.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688578_20260430_WREW.\"><\/object><a id=\"wp-block-file--media-f3b4113a-358a-4e8e-a0cb-923a034dd7b4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688578_20260430_WREW.pdf\">688578_20260430_WREW<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688578_20260430_WREW.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f3b4113a-358a-4e8e-a0cb-923a034dd7b4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China&#8217;s regulatory authorities have granted Breakthrough Therapy&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[138,16,29,922],"class_list":["post-64299","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-allist-pharmaceuticals","tag-cancer","tag-combination-therapy","tag-sha-688578"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China&#039;s regulatory authorities have granted Breakthrough Therapy Designation (BTD) for its investigational combination of glecirasib and AST24082 as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations and PD-L1 expression &lt; 50%.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64299\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate\" \/>\n<meta property=\"og:description\" content=\"Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China&#039;s regulatory authorities have granted Breakthrough Therapy Designation (BTD) for its investigational combination of glecirasib and AST24082 as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations and PD-L1 expression &lt; 50%.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64299\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T06:15:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64299#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64299\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate\",\"datePublished\":\"2026-04-30T06:15:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64299\"},\"wordCount\":441,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Allist Pharmaceuticals\",\"Cancer\",\"Combination therapy\",\"SHA: 688578\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64299#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64299\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64299\",\"name\":\"Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-30T06:15:28+00:00\",\"description\":\"Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China's regulatory authorities have granted Breakthrough Therapy Designation (BTD) for its investigational combination of glecirasib and AST24082 as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations and PD-L1 expression &lt; 50%.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64299#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64299\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64299#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate - Insight, China&#039;s Pharmaceutical Industry","description":"Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China's regulatory authorities have granted Breakthrough Therapy Designation (BTD) for its investigational combination of glecirasib and AST24082 as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations and PD-L1 expression &lt; 50%.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64299","og_locale":"en_US","og_type":"article","og_title":"Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate","og_description":"Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China's regulatory authorities have granted Breakthrough Therapy Designation (BTD) for its investigational combination of glecirasib and AST24082 as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations and PD-L1 expression &lt; 50%.","og_url":"https:\/\/flcube.com\/?p=64299","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-30T06:15:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64299#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64299"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate","datePublished":"2026-04-30T06:15:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64299"},"wordCount":441,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Allist Pharmaceuticals","Cancer","Combination therapy","SHA: 688578"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64299#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64299","url":"https:\/\/flcube.com\/?p=64299","name":"Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-30T06:15:28+00:00","description":"Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China's regulatory authorities have granted Breakthrough Therapy Designation (BTD) for its investigational combination of glecirasib and AST24082 as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations and PD-L1 expression &lt; 50%.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64299#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64299"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64299#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64299"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64299\/revisions"}],"predecessor-version":[{"id":64302,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64299\/revisions\/64302"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}